You are here

Biosimilar CT-P13 Demonstrates Equivalent Safety and Efficacy in Treatment of Crohn’s Disease

Choice of Drug Could Be Based on Lower Cost

A study published in the Annals of Internal Medicine found that the infliximab biosimilar CT-P13 (Celltrion Inc.) demonstrated equivalent safety and efficacy to the anti-tumor necrosis factor (TNF) monoclonal antibody for treating Crohn’s disease in infliximab-naïve patients.

TNF inhibitors, including infliximab, have improved the management of inflammatory bowel disease. As CT-P13 demonstrated efficacy and safety for some inflammatory arthritides, it was approved for Crohn’s disease on that basis, without specific studies examining its effects in Crohn’s disease.

Researchers from Caisse Nationale de l’Assurance Maladie in Paris, France, studied a French nationwide database to compare the effectiveness and safety of CT-P13 and the reference product (infliximab). The study included 5,050 infliximab-naïve patients who commenced treatment with infliximab (n = 2,551) or CT-P13 (n = 2,499). Researchers found that CT-P13 demonstrated equivalent efficacy to infliximab and they observed no difference regarding safety outcomes.

Based on the study’s findings, it’s possible that choosing between infliximab and CT-P13 could be based primarily on cost.

Source:, December 11, 2018

Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug